Cargando…

Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancer

Detalles Bibliográficos
Autores principales:	Nagy, Zsuzsanna, Jeselsohn, Rinath
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026358/ https://www.ncbi.nlm.nih.gov/pubmed/36950546 http://dx.doi.org/10.3389/fonc.2023.1155540

Ejemplares similares

ESR1 fusions and therapeutic resistance in metastatic breast cancer
por: Nagy, Zsuzsanna, et al.
Publicado: (2023)

Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer
por: Kuang, Yanan, et al.
Publicado: (2018)

How drug resistance takes shape
por: Jeselsohn, Rinath, et al.
Publicado: (2016)

Detection of ESR1 Mutations Based on Liquid Biopsy in Estrogen Receptor-Positive Metastatic Breast Cancer: Clinical Impacts and Prospects
por: Liao, Hao, et al.
Publicado: (2020)

Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance
por: Li, Li, et al.
Publicado: (2020)

The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells
por: Fanning, Sean W, et al.
Publicado: (2018)

Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer
por: Gerratana, Lorenzo, et al.
Publicado: (2020)

ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer
por: Lei, Jonathan T., et al.
Publicado: (2018)

Elucidation of Novel Therapeutic Targets for Breast Cancer with ESR1-CCDC170 Fusion
por: Jeong, Jae Heon, et al.
Publicado: (2021)

The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
por: Grinshpun, Albert, et al.
Publicado: (2023)

Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer
por: Reinert, Tomas, et al.
Publicado: (2017)

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer
por: Hartmaier, R J, et al.
Publicado: (2018)

ESR1 mutations in metastatic lobular breast cancer patients
por: Desmedt, Christine, et al.
Publicado: (2019)

RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer
por: Dustin, Derek, et al.
Publicado: (2020)

Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status
por: Downton, Teesha, et al.
Publicado: (2022)

ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis
por: Urso, Loredana, et al.
Publicado: (2021)

microRNA-Dependent Modulation of Genes Contributes to ESR1's Effect on ERα Positive Breast Cancer
por: Gao, Shan, et al.
Publicado: (2020)

Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer
por: Li, Zheqi, et al.
Publicado: (2022)

ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy
por: Reinert, Tomás, et al.
Publicado: (2020)

ESR2 Drives Mesenchymal-to-Epithelial Transition in Triple-Negative Breast Cancer and Tumorigenesis In Vivo
por: Piperigkou, Zoi, et al.
Publicado: (2022)

Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer
por: Gou, Xuxu, et al.
Publicado: (2021)

DNAJC12 as a Mediator Between ESR1 and ERBB4 in Breast Carcinoma Cells
por: Lin, Mianjie, et al.
Publicado: (2021)

Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis
por: Najim, Omar, et al.
Publicado: (2023)

Corrigendum: Metastatic Extramammary Paget’s Disease: Pathogenesis and Novel Therapeutic Approach
por: Fukuda, Keitaro, et al.
Publicado: (2018)

Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series
por: Brett, Jamie O, et al.
Publicado: (2022)

Corrigendum: Flavonoid Derivative of Cannabis Demonstrates Therapeutic Potential in Preclinical Models of Metastatic Pancreatic Cancer
por: Moreau, Michele, et al.
Publicado: (2020)

Unusual phylogenetic tree and circulating actionable ESR1 mutations in an aggressive luminal/HER2-low breast cancer: Case report
por: Allegretti, Matteo, et al.
Publicado: (2023)

Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer
por: Gou, Xuxu, et al.
Publicado: (2023)

Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer
por: Lei, Jonathan T., et al.
Publicado: (2018)

The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer
por: Vitale, Silvia R., et al.
Publicado: (2022)

Corrigendum: Cross-resistance among sequential cancer therapeutics: An emerging issue
por: Loria, Rossella, et al.
Publicado: (2022)

ESR1 mutations in breast cancer
por: Clatot, Florian, et al.
Publicado: (2017)

ESR1 Methylation Measured in Cell-Free DNA to Evaluate Endocrine Resistance in Metastatic Breast Cancer Patients
por: Bos, Manouk K., et al.
Publicado: (2022)

Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer
por: Harrod, A, et al.
Publicado: (2017)

Expression Analysis of Long Non-Coding RNAs Related With FOXM1, GATA3, FOXA1 and ESR1 in Breast Tissues
por: Hassani, Bita, et al.
Publicado: (2021)

ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target
por: Cheng, Xuan, et al.
Publicado: (2021)

Corrigendum: Individualized Prediction of Survival Benefit From Locoregional Surgical Treatment for Patients With Metastatic Breast Cancer
por: Zheng, Yajuan, et al.
Publicado: (2020)

Corrigendum: STAT5a Confers Doxorubicin Resistance to Breast Cancer by Regulating ABCB1
por: Li, Zhaoqing, et al.
Publicado: (2022)

CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients
por: Crucitta, Stefania, et al.
Publicado: (2023)

Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients
por: Niu, Jiaxin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_r4sjq9tsqtminp6e8m98km83hr